Company Overview


Unilife is a U.S. based medical device company focused on the design, development, manufacture and supply of a proprietary range of retractable syringes. Primary target customers for our products include pharmaceutical manufacturers, suppliers of medical equipment to healthcare facilities and patients who self-administer prescription medication. All of our syringes incorporate automatic and fully-integrated safety features which are designed to protect those at risk of needlestick injuries and unsafe injection practices. We are ISO 13485 certified and have FDA-registered medical device manufacturing facilities in Pennsylvania.


Our main product is the UnifillTM ready-to-fill syringe, which is designed to be supplied to pharmaceutical manufacturers in a form that is ready for filling with their injectable drugs and vaccines. We have a strategic partnership with sanofi-aventis, who has the exclusive right to negotiate for the purchase of the Unifill syringe and is funding our industrialization program. In addition, we have retained the right to negotiate with other pharmaceutical companies seeking to utilize the Unifill syringe with drugs and vaccines marketed in therapeutic areas outside of those secured exclusively by sanofi-aventis.


News & Events

Unilife (UNIS) Completes Use of At-The-Market Financing (ATM) Facility

Final use of ATM raises $12.4MM in net proceeds to offset much of one-time acceleration in investment from fiscal Q4 2014 Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS; ASX: UNS), a developer and supplier of injectable drug delivery systems, today announced that it has completed the At-The-Market (ATM) facility with

Unilife Accelerates Investment to Meet Increasing Demand from New and Existing C

      Revenue for fiscal year 2014 anticipated to be at the high end of the $12 million to $15 million guidance range Unifill commercial sales to commence this fiscal quarter and accelerate through FY2015 and FY2016 First commercial Unifill Finesse manufacturing line operational with additional li

Unilife (UNIS) CEO: OrbiMed Deal Only the Beginning

Shares of Unilife spiked this week after it revealed a $60 million debt financing agreement with healthcare investment firm OrbiMed. Unilife CEO Alan Shortall expects to build on those gains as additional deals and customer wins are announced. $40 million was funded to Unilife at the closing of the deal, which it will use to run

Unilife (UNIS) Secures $60 Million Debt Financing with OrbiMed Advisors

Unilife Corporation ("Unilife" or "Company") UNIS +15.47%(asx:UNS) today announced that it has entered into a $60 million debt financing agreement with an affiliate of OrbiMed ("OrbiMed"). $40 million was funded to Unilife at the closing of the deal. Provided the Company is in compliance with the terms of the agreement, two

Follow Us
Email Alerts
  • Name: